Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf

A method for treating a major menorrhagia bleeding episode in a subject with severe Type 1 von Willebrand Disease (VWD) comprising:

• a) administering a first dose of 50-75 IU/kg rVWF to the subject;
• b) administering a plurality of second doses of 40-60 IU/kg rVWF to the subject, wherein each of the doses is administered every 8-12 hours for 3 days such that a trough level of VWF:RCo is maintained at at least 0.30 IU/mL or a trough level of VWF:GPIbM or VWF:GPIbR is maintained that is equivalent to the trough level of VWF:RCo of at least 0.30 IU/mL;
• and
• c) administering a third dose of 40-60 IU/kg rVWF to the subject once a day for the remaining duration of the bleeding episode;
• wherein the total duration of steps (a)-(c) is no more than about 7 days.

A method for treating a major menorrhagia bleeding episode in a subject with severe Type 2 or Type 3 von Willebrand Disease (VWD) comprising:

• a) administering a first dose of 60-80 IU/kg rVWF to the subject;
• b) administering a plurality of second doses of 40-60 IU/kg rVWF to the subject, wherein each of the doses is administered every 8-12 hours for 3 days such that a trough level of VWF:RCo is maintained at at least 0.30 IU/mL or a trough level of VWF:GPIbM or VWF:GPIbR is maintained that is equivalent to the trough level of VWF:RCo of at least 0.30 IU/mL;
• and
• c) administering a third dose of 40-60 IU/kg rVWF to the subject once a day for the remaining duration of the bleeding episode;
• wherein the total duration of steps (a)-(c) is no more than about 7 days.